RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptive Biotechnologies Stock

Adaptive Biotechnologies Net Income 2025

Adaptive Biotechnologies Net Income

-112.71 M USD

Ticker

ADPT

ISIN

US00650F1093

WKN

A2PLR5

In 2025, Adaptive Biotechnologies's profit amounted to -112.71 M USD, a -29.33% increase from the -159.49 M USD profit recorded in the previous year.

The Adaptive Biotechnologies Net Income history

YEARNET INCOME (undefined USD)
2030e-
2029e-
2028e-
2027e-
2026e-
2025e-
2024-
2023-
2022-
2021-
2020-
2019-
2018-
2017-

Adaptive Biotechnologies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adaptive Biotechnologies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adaptive Biotechnologies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adaptive Biotechnologies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adaptive Biotechnologies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adaptive Biotechnologies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adaptive Biotechnologies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adaptive Biotechnologies’s growth potential.

Adaptive Biotechnologies Revenue, EBIT and net profit per share

DateAdaptive Biotechnologies RevenueAdaptive Biotechnologies EBITAdaptive Biotechnologies Net Income
2030e569.16 M undefined0 undefined0 undefined
2029e480.52 M undefined-31.21 M undefined-31.06 M undefined
2028e392.5 M undefined-11.58 M undefined-12.43 M undefined
2027e337.35 M undefined-45.76 M undefined-52.5 M undefined
2026e276.06 M undefined-75.75 M undefined-91.86 M undefined
2025e237.35 M undefined-109.54 M undefined-112.71 M undefined
2024178.96 M undefined-155.34 M undefined-159.49 M undefined
2023170.28 M undefined-201.61 M undefined-225.25 M undefined
2022185.3 M undefined-198.6 M undefined-200.2 M undefined
2021154.3 M undefined-209 M undefined-207.3 M undefined
202098.4 M undefined-152.8 M undefined-146.2 M undefined
201985.1 M undefined-78.4 M undefined-69.6 M undefined
201855.7 M undefined-49.8 M undefined-46.3 M undefined
201738.4 M undefined-43.7 M undefined-42.7 M undefined

Adaptive Biotechnologies stock margins

The Adaptive Biotechnologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adaptive Biotechnologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adaptive Biotechnologies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adaptive Biotechnologies's sales revenue. A higher gross margin percentage indicates that the Adaptive Biotechnologies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adaptive Biotechnologies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adaptive Biotechnologies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adaptive Biotechnologies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adaptive Biotechnologies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adaptive Biotechnologies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adaptive Biotechnologies Margin History

Adaptive Biotechnologies Gross marginAdaptive Biotechnologies Profit marginAdaptive Biotechnologies EBIT marginAdaptive Biotechnologies Profit margin
2030e59.72 %0 %0 %
2029e59.72 %-6.5 %-6.46 %
2028e59.72 %-2.95 %-3.17 %
2027e59.72 %-13.56 %-15.56 %
2026e59.72 %-27.44 %-33.27 %
2025e59.72 %-46.15 %-47.49 %
202459.72 %-86.81 %-89.12 %
202355.63 %-118.4 %-132.29 %
202268.75 %-107.18 %-108.04 %
202168.05 %-135.45 %-134.35 %
202077.13 %-155.28 %-148.58 %
201973.8 %-92.13 %-81.79 %
201864.63 %-89.41 %-83.12 %
201759.37 %-113.8 %-111.2 %

Adaptive Biotechnologies Aktienanalyse

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corp is a biotechnology company specializing in the discovery and development of therapies for various diseases. It was founded in 2009 by brothers Chad and Harlan Robins in Seattle, USA. Adaptive Biotechnologies Corp is a leading provider of immune sequencing technology and analysis of T-cell and B-cell receptors. The company's business model is based on the development of therapies through the analysis of patient samples. The company's artificial intelligence and machine learning make immune systems visible to fight pathogens. By creating an accurate profile of patients' immune systems, the company enables the development of personalized therapies tailored to the individual needs and disease profiles of patients. The company is divided into several divisions, including oncology, immunology, and research and development of therapeutics. In the field of oncology, Adaptive Biotechnologies Corp focuses on the discovery of cancer therapies by identifying T-cell receptor characteristics of patients who have responded to cancer treatments. The team at Adaptive Biotechnologies Corp works with various pharmaceutical and biotech companies to advance the discovery of cancer therapeutics. In the field of immunology, the company has also focused on the identification of rare and severe immune disorders to enable more targeted diagnostics and treatment. Adaptive Biotechnologies Corp provides immune and other research instruments and sample processing systems for the study of antigen-antibody interactions. In addition, the company has also developed its own products, including the ImmunTraCkeR® test system, which analyzes the immune response of critically ill patients to improve ongoing therapies or enable early detection of new diseases. Other products include the immunoSEQ® assay kit and the clonoSEQ® assay kit, which are used for sequencing patients' immune systems. These test systems allow for the detection of minimal residual routes of T-cell or B-cell receptors in patients' blood, enabling better monitoring of cancer and the creation of personalized treatment plans. Adaptive Biotechnologies Corp is particularly highly regarded in the pharmaceutical and biotech industry for novel therapeutics and biologics, and has already collaborated with many reputable companies including Genentech, Roche, and Microsoft. The company's mission is to accelerate progress in medical research and the development of new therapies to help patients around the world. In recent times, the company has played a crucial role in testing point-of-care COVID rapid tests. For example, it is working with universities such as the University of Pennsylvania to explore ways in which the tests can be utilized. The company is also developing its own COVID-19 tests that have undergone clinical testing. Overall, Adaptive Biotechnologies Corp is a successful biotechnology company with a unique focus on personalized medicine and therapies tailored to specific patient immune profiles. With its innovative products and services, as well as partnerships with industry leaders, the company has revolutionized the bio-IT world and become one of the leading companies in the industry. Adaptive Biotechnologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Adaptive Biotechnologies's Profit Margins

The profit margins of Adaptive Biotechnologies represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Adaptive Biotechnologies's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Adaptive Biotechnologies's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Adaptive Biotechnologies's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Adaptive Biotechnologies’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Adaptive Biotechnologies stock

How much profit has Adaptive Biotechnologies made this year?

Adaptive Biotechnologies has made -112.71 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -29.33% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Adaptive Biotechnologies publish its earnings?

Adaptive Biotechnologies publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Adaptive Biotechnologies?

The profits of Adaptive Biotechnologies are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Adaptive Biotechnologies?

You can learn more about the earnings of Adaptive Biotechnologies by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Adaptive Biotechnologies pay?

Over the past 12 months, Adaptive Biotechnologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptive Biotechnologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptive Biotechnologies?

The current dividend yield of Adaptive Biotechnologies is .

When does Adaptive Biotechnologies pay dividends?

Adaptive Biotechnologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptive Biotechnologies?

Adaptive Biotechnologies paid dividends every year for the past 0 years.

What is the dividend of Adaptive Biotechnologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptive Biotechnologies located?

Adaptive Biotechnologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptive Biotechnologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptive Biotechnologies from 10/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2025.

When did Adaptive Biotechnologies pay the last dividend?

The last dividend was paid out on 10/12/2025.

What was the dividend of Adaptive Biotechnologies in the year 2024?

In the year 2024, Adaptive Biotechnologies distributed 0 USD as dividends.

In which currency does Adaptive Biotechnologies pay out the dividend?

The dividends of Adaptive Biotechnologies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Adaptive Biotechnologies

Our stock analysis for Adaptive Biotechnologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptive Biotechnologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.